|
Post by celo on Feb 22, 2023 8:27:38 GMT -5
United Revenues dropped from 3rd qtr to 4th qtr. Tyvaso net sales dropped from 257 to 241 million. I wonder if the lack of using the United Tyvaso device is eating away at income. Instead patients are using the mannkind inhaler which is a lot cheaper.
|
|
|
Post by Clement on Feb 22, 2023 8:34:38 GMT -5
For Q4, UTHR reported Net Tyvaso (both neb and dpi) sales of $242.3M. I'm wondering how much of that is DPI. 40%? 50%?
|
|
|
Post by celo on Feb 22, 2023 8:41:19 GMT -5
4th quarter Cost of sales $55.9m 3rd quarter Cost of sales $37.1m MNKD Revenue $16.566m of that(collaborations and services $10.346m, Royalties — collaborations $6.220m) Lets hope UTHR's cost for others in the 4th quarter is similar and the increase is mostly MNKD collab, and royalties.
Probably a little too hopeful, but MNKD last quarters loss was $14.432m. Would love to see break even.
With everything being even for cost of sales from one quarter to the next besides the MNKD collar and royalties, that would mean an increase of 18.8 million in additional collaboration and royalty payments or a total of 35.3 million for the qtr to Mannkind.
|
|
|
Post by sayhey24 on Feb 22, 2023 9:30:33 GMT -5
4th quarter Cost of sales $55.9m 3rd quarter Cost of sales $37.1m MNKD Revenue $16.566m of that(collaborations and services $10.346m, Royalties — collaborations $6.220m) Lets hope UTHR's cost for others in the 4th quarter is similar and the increase is mostly MNKD collab, and royalties.
Probably a little too hopeful, but MNKD last quarters loss was $14.432m. Would love to see break even.
Is .4465 a good number to use to determine MNKD Revenue on Tyvaso DPI CoS? $55.9 x .4465 = $24.95M I guess we will find out tomorrow.
|
|
|
Post by hellodolly on Feb 22, 2023 20:05:44 GMT -5
UTHR Cost of Sales increased from $116.7 million to $146.7 million and is followed by this note: "The increase in cost of sales for the year ended December 31, 2022, as compared to the same period in 2021, was primarily due to an increase in royalty expense and product costs for Tyvaso DPI following the commercial launch of the product in June 2022." (page 51) My guess is they front loaded a large amount of Tyvaso DPI in advance of the launch and it was that recognition of the large inventory build, leading up to the launch in June 2022, that ate into their bottom line and was recognized in this Quarter. I expect this to go away or drop to a stable number over the next few quarters.
|
|
|
Post by casualinvestor on Feb 22, 2023 22:31:40 GMT -5
United Revenues dropped from 3rd qtr to 4th qtr. Tyvaso net sales dropped from 257 to 241 million. I wonder if the lack of using the United Tyvaso device is eating away at income. Instead patients are using the mannkind inhaler which is a lot cheaper. Looks like the PAP (patient assistance program) may be part of it. High Medicare part D copays for DPI is adding patients to the assistance program. Shouldn't affect calculations for MNKD revenue based off of CoS though One odd thing about CoS for 2021 (no DPI in the mix back then) is that it went up from Q3 to Q4 by about 22% when total revenue went down a few %. If that is just a seasonal thing, MNKD revenue might be a little less than expected from a straight ration of CoS from 2022 Q3 vs Q4
|
|
|
Post by hellodolly on Feb 23, 2023 5:55:12 GMT -5
United Revenues dropped from 3rd qtr to 4th qtr. Tyvaso net sales dropped from 257 to 241 million. I wonder if the lack of using the United Tyvaso device is eating away at income. Instead patients are using the mannkind inhaler which is a lot cheaper. Looks like the PAP (patient assistance program) may be part of it. High Medicare part D copays for DPI is adding patients to the assistance program. Shouldn't affect calculations for MNKD revenue based off of CoS though One odd thing about CoS for 2021 (no DPI in the mix back then) is that it went up from Q3 to Q4 by about 22% when total revenue went down a few %. If that is just a seasonal thing, MNKD revenue might be a little less than expected from a straight ration of CoS from 2022 Q3 vs Q4 Purchase of V-Go in that figure?
|
|
|
Post by casualinvestor on Feb 23, 2023 10:07:27 GMT -5
V-Go won't show on UTHR's sheets at all.
Above there's speculation that MNKD's DPI-related royalty and manufacturing revenue can be estimated from looking at UTHR's CoS. My point is that from Q3 2021 to Q4 2021 UTHR's CoS went up 22% without any increase in sales at a time when DPI was not being sold. So if there's some seasonal CoS shift from Q3 to Q4 that's unrelated to DPI, then a straight ratio will be misleading.
Anyone know if PAP sales will show up on Symphony?
|
|
|
Post by wyattdog on Feb 23, 2023 10:36:14 GMT -5
U.S. RESEARCH ROUNDUP- 10:25 AM ET, 02/23/2023 - Reuters United Therapeutics Corp : JP Morgan raises target price to $280 from $265 Credit Suisse raises target price to $293 from $266 Jefferies cuts target price to $317 from $320
|
|
|
Post by harryx1 on Feb 23, 2023 14:26:25 GMT -5
|
|
|
Post by Clement on Mar 6, 2023 6:52:07 GMT -5
United Therapeutics Corporation announced that Michael Benkowitz, President and Chief Operating Officer, will provide an overview and update on the company’s business during a fireside chat session at the Cowen 43rd Annual Health Care Conference in Boston. The session will take place on Tuesday, March 7, 2023, from 9:10 a.m. to 9:40 a.m., Eastern Standard Time, and can be accessed via a live webcast on the United Therapeutics website at ir.unither.com/events-and-presentations.
|
|
|
Post by Clement on Mar 8, 2023 9:03:47 GMT -5
United Therapeutics Corporation announced that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will provide an overview and update on the company’s business during a fireside chat session at the Oppenheimer 33rd Annual Healthcare Conference. The session will take place on Monday, March 13, 2023, from 11:20 a.m. to 11:50 a.m., Eastern Daylight Time, and can be accessed via a live webcast on the United Therapeutics website at ir.unither.com/events-and-presentations.
|
|
|
Post by mymann on Mar 14, 2023 21:36:51 GMT -5
CEO sold again today. Scheduled or not, selling shares for almost 3 weeks almost every day. What's going on?
|
|
|
Post by sportsrancho on Mar 15, 2023 8:42:08 GMT -5
CEO sold again today. Scheduled or not, selling shares for almost 3 weeks almost every day. What's going on? Seems to me she’s taking profit while she can before the market collapses.
|
|
|
Post by neil36 on Mar 20, 2023 18:27:44 GMT -5
|
|